Skip to main content
KYONGBO PHARMACEUTICAL CO., LTD. logo

KYONGBO PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 214390 ISIN · KR7214390007 LEI · 988400YKOM1CHDS6R917 KO Manufacturing
Open in API
Filings indexed 206 across all filing types
Latest filing 2026-02-24 Notice of Dividend Amou…
Country KR South Korea
Listing KO 214390

About KYONGBO PHARMACEUTICAL CO., LTD.

https://www.kbpharma.co.kr/en/home

Kyongbo Pharmaceutical Co., Ltd. is a pharmaceutical company specializing in the research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished drug products. The company also operates as a Contract Development and Manufacturing Organization (CDMO), offering integrated services from early-stage development through to commercial cGMP production. Its core product portfolio includes a diverse range of APIs, such as sterile and non-sterile cephalosporins, carbapenem antibiotics, and high-potency cytotoxic anti-cancer agents. In addition to APIs, the company manufactures finished dosage forms, including solid oral medications and sterile injectables. Kyongbo Pharmaceutical utilizes dedicated and segregated manufacturing facilities to produce its specialized product lines, supported by a strong commitment to research and innovation in API synthesis.

Recent filings

Filing Released Lang Actions
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Kyongbo Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the date of the upcoming general meeting of shareholders. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2026-02-24 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (Kyungbo Pharmaceutical) announcing a significant change (over 15% or 30%) in its financial structure (revenue, operating profit, net income) compared to the previous fiscal year. This is a standard 'Earnings Release' (ER) type of disclosure in the Korean market (DART system), providing preliminary financial highlights before the final audited report is published. It fits the definition of an Earnings Release as it provides key financial highlights and the reasons for the variance.
2026-02-02 Korean
[기재정정]신규시설투자등
Capital/Financing Update Classification · 98% confidence The document is a regulatory filing from Kyobo Pharmaceutical regarding a 'Correction Report' (정정신고) for a 'New Facility Investment' (신규시설투자등). It details changes to the investment amount and provides updated financial figures related to capital expenditure. Since this is a specific regulatory announcement regarding corporate investment activities and does not fit into the other specialized categories like M&A or Share Issues, it is classified as a Regulatory Filing (RNS).
2026-02-02 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 95% confidence The document is titled as a provisional (잠정) operating performance disclosure (영업(잠정)실적(공정공시)) for the period 2025-07-01 to 2025-09-30, with comparative data for previous quarters and years. It contains summarized financial figures such as sales, operating profit, and net income, but it is explicitly stated as provisional and unaudited. The document length is short (2040 characters) and it is a disclosure of preliminary financial results rather than a full comprehensive financial report. This type of document is typically an Earnings Release (ER) as it announces key financial results for a quarter or period without the full detailed financial statements or management discussion. It is not an Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains actual financial data, not just a notice. Therefore, the best classification is Earnings Release (ER). 9M 2025
2025-10-31 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' which translates to 'Report on Ownership Status of Specific Securities by Executives and Major Shareholders.' It includes detailed information about the ownership of securities by an executive named 정 희 록, including dates, share counts, and ownership percentages. The document is a formal report submitted to regulatory bodies such as the Securities and Futures Commission and the Korea Exchange. This type of document corresponds to a Major Shareholding Notification, which reports changes in significant share ownership levels by insiders or major shareholders. The document length is 2407 characters, which is consistent with a detailed ownership notification rather than a full financial report or announcement. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2025-10-21 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Kyungbo Pharmaceutical. It details specific transactions (gifts/transfers) of shares by directors and major shareholders. In the context of financial filings, this is a report of insider trading or changes in major shareholding status, which falls under the 'Director's Dealing' (DIRS) category as it tracks personal share transactions by company directors and executives.
2025-09-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.